Magnetar Financial’s ADC Therapeutics ADCT Stock Holding History

Magnetar Financial’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Hold	39,092	–	–	﹤0.01%	946
2025 Q4	$138K	Hold	39,092	–	–	﹤0.01%	831
2025 Q3	$156K	Hold	39,092	–	–	﹤0.01%	793
2025 Q2	$105K	Sell	39,092 -16,670	-30%	-$35.1K	﹤0.01%	839
2025 Q1	$78.6K	Hold	55,762	–	–	﹤0.01%	708
2024 Q4	$111K	Hold	55,762	–	–	﹤0.01%	574
2024 Q3	$176K	Hold	55,762	–	–	﹤0.01%	479
2024 Q2	$176K	Hold	55,762	–	–	﹤0.01%	469
2024 Q1	$250K	Hold	55,762	–	–	0.01%	335
2023 Q4	$92.6K	Hold	55,762	–	–	﹤0.01%	344
2023 Q3	$50K	Hold	55,762	–	–	﹤0.01%	422
2023 Q2	$120K	Hold	55,762	–	–	﹤0.01%	442
2023 Q1	$109K	Sell	55,762 -71,106	-56%	-$262K	﹤0.01%	560
2022 Q4	$487K	Sell	126,868 -40,000	-24%	-$160K	0.01%	607
2022 Q3	$804K	Sell	166,868 -830	-0.5%	-$6.01K	0.01%	754
2022 Q2	$1.33K	Hold	167,698	–	–	0.01%	870
2022 Q1	$2.46M	Buy	167,698 +40,000	+31%	+$635K	0.03%	620
2021 Q4	$2.58M	Buy	127,698 +2,500	+2%	+$60.3K	0.03%	620
2021 Q3	$3.4M	Sell	125,198 -15,000	-11%	-$384K	0.03%	487
2021 Q2	$3.41K	Buy	140,198 +30,000	+27%	+$696K	0.03%	489
2021 Q1	$2.69M	Hold	110,198	–	–	0.03%	508
2020 Q4	$3.53M	Sell	110,198 -1,513,012	-93%	-$49.6M	0.05%	277
2020 Q3	$49.4M	Buy	1,623,210 +59,772	+4%	+$2.59M	0.87%	23
2020 Q2	$64.4M	Buy	+1,563,438	New	+$59.3M	1.9%	15

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Magnetar Financial's ADCT Position: Q1 2026 in Review

Magnetar Financial held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 39,092 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Magnetar Financial first reported a position in ADCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $64.4M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Magnetar Financial held 39,092 shares of ADC Therapeutics worth $147K as of Q1 2026.
Magnetar Financial left its ADC Therapeutics share count unchanged in Q1 2026.
ADC Therapeutics made up ﹤0.01% of Magnetar Financial's portfolio in Q1 2026, its #946 holding.
Magnetar Financial first reported a position in ADC Therapeutics in Q2 2020 and has held it in 24 quarters since.
Magnetar Financial's ADC Therapeutics position peaked at $64.4M in Q2 2020.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.